Mechanism-Based Tumor-Targeting Drug Delivery System
Bioconjugate Chem., Vol. 21, No. 5, 2010 987
(10) Leamon, C. P., and Reddy, J. A. (2004) Folate-targeted
chemotherapy. AdV. Drug DeliVery ReV. 56, 1127–1141.
(11) Lu, Y., and Low, P. S. (2002) Folate-mediated delivery of
macromolecular anticancer therapeutic agents. AdV. Drug De-
liVery ReV. 54, 675–693.
(12) Lee, J. W., Lu, J. Y., Low, P. S., and Fuchs, P. L. (2002)
Synthesis and evaluation of taxol-folic acid conjugates as targeted
antineoplastics. Bioorg. Med. Chem. 10, 2397–2414.
(13) Chu, T. C., Marks, J. W., III, Lavery, L. A., Faulkner, S.,
Rosenblum, M. G., Ellington, A. D., and Matthew Levy, M.
(2006) Aptamer: toxin conjugates that specifically target prostate
tumor cells. Cancer Res. 66, 5989–5992.
(28) Britten, R. A., and Green, J. A. (1992) Cellular glutathione
and glutathione S-transferase activity in human ovarian tumor
biopsies following exposure to alkylating agents. Int. J. Radiat.
Oncol. Biol. Phys. 24, 527–531.
(29) Anderson, M. E. (1989) Enzymatic and chemical methods for
determination of glutathione, In Glutathione: Chemical, Bio-
chemical, and Medical Aspects (Dolphin, D., Avramovic, O.,
and Poulson, R., Eds.) pp 340-365, John Wiley and Sons,
Toronto.
(30) Schiff, P. B., Fant, J., and Horwitz, S. B. (1979) Promotion
of microtubule assembly in Vitro by taxol. Nature 277, 665–
667.
(14) Farokhzad, O. C., Cheng, J., Teply, B. A., Sherifi, I., Jon, S.,
Kantoff, P. W., Richie, J. P., and Langer, R. (2006) Targeted
nanoparticle-aptamer bioconjugates for cancer chemotherapy in
vivo. Proc. Natl. Acad. Sci. U.S.A. 103, 6315–6320.
(15) Wagner, E., Curiel, D., and Cotten, M. (1994) Delivery of
drugs, proteins and genes into cells using transferrin as a ligand
for receptor-mediated endocytosis. AdV. Drug DeliVery ReV. 14,
113–135.
(16) Nagy, A., Schally, A. V., Halmos, G., Armatis, P., Cai, R.-
Z., Csernus, V., Kovacs, M., Koppan, M., Szepeshazi, K., and
Kahan, Z. (1998) Synthesis and biological evaluation of cytotoxic
analogs of somatostatin containing doxorubicin or its intensely
potent derivative, 2-pyrrolinodoxorubicin. Proc. Natl. Acad. Sci.
U.S.A. 95, 1794–1799.
(17) Luo, Y., Bernshaw, N. J., Lu, Z.-R., Kopecek, J., and
Prestwich, G. D. (2002) Targeted delivery of doxorubicin by
HPMA copolymer-hyaluronan bioconjugates. Pharm. Res. 19,
396–402.
(18) Chen, J., Chen, S., Zhao, X., Kuznetsova, L. V., Wong, S. S.,
and Ojima, I. (2008) Functionalized single-walled carbon nano-
tubes as rationally designed vehicles for tumor-targeted drug
delivery. J. Am. Chem. Soc. 130, 16778–16785.
(19) Russell-Jones, G., McTavish, K., McEwan, J., Rice, J., and
Nowotnik, D. (2004) Vitamin-mediated targeting as a potential
mechanism to increase drug uptake by tumors. J. Inorg. Biochem.
98, 1625–1633.
(20) Russell-Jones, G., and McEwan, J. (Access Pharmaceuticals
Australia Pty. Ltd., Australia) (2004) Amplification of biotin-
mediated targeting, PCT WO2004/045647.
(21) Reddy, J. A., Westrick, E., Vlahov, I., Howard, S. J.,
Santhapuram, H. K., and Leamon, C. P. (2006) Folate receptor
specific anti-tumor activity of folate-mitomycin conjugates.
Cancer Chemother. Pharmacol. 58, 229–236.
(22) Leamon, C. P., Reddy, J. A., Vlahov, I. R., Vetzel, M., Parker,
N., Nicoson, J. S., Xu, L.-C., and Westrick, E. (2005) Synthesis
and biological evaluation of EC72: a new folate-targeted
chemotherapeutic. Bioconjugate Chem. 16, 803–811.
(23) Mosmann, T. (1983) Rapid colorimetric assay for cellular
growth and survival: application to proliferation and cytotoxicity
assays. J. Immunol. Methods 65, 55–63.
(31) Vredenburg, M. R., Ojima, I., Veith, J., Pera, P., Kee, K.,
Cabral, F., Sharma, A., Kanter, P., and Bernacki, R. J. (2001)
Effects of orally active taxanes on P-glycoprotein modulation
and colon and breast carcinoma drug resistance. J. Natl. Cancer
Inst. 93, 1234–1245.
(32) Ojima, I., Slater, J. C., Michaud, E., Kuduk, S. D., Bounaud,
P.-Y., Vrignaud, P., Bissery, M.-C., Veith, J., Pera, P., and
Bernacki, R. J. (1996) Syntheses and structure-activity relation-
ships of the second generation antitumor taxoids. exceptional
activity against drug-resistant cancer cells. J. Med. Chem. 39,
3889–3896.
(33) Ojima, I., Slater, J. S., Kuduk, S. D., Takeuchi, C. S., Gimi,
R. H., Sun, C.-M., Park, Y. H., Pera, P., Veith, J. M., and
Bernacki, R. J. (1997) Syntheses and structure-activity relation-
ships of taxoids derived from 14ꢀ-hydroxy-10-deacetylbaccatin
III. J. Med. Chem. 40, 267–278.
(34) Ojima, I., Wang, T., Miller, M. L., Lin, S., Borella, C., Geng,
X., Pera, P., and Bernacki, R. J. (1999) Syntheses and structure-
activity relationships of new second-generation taxoids. Bioorg.
Med. Chem. Lett. 9, 3423–3428.
(35) Ojima, I., Lin, S., and Wang, T. (1999) The recent advances
in the medicinal chemistry of taxoids with novel ꢀ-amino acid
side chains. in the chemistry and biology of ꢀ-amino acids. Curr.
Med. Chem. 6, 927–954.
(36) Geney, R., Chen, J., and Ojima, I. (2005) Recent advance in
the new generation taxane anticancer agents. Med. Chem. 1, 125–
139.
(37) Ojima, I., Chen, J., Sun, L., Borella, C. P., Wang, W., Miller,
M. L., Lin, S., Geng, X., Kuznetsova, L., Qu, C., Gallager, D.,
Zhao, X., Zanardi, I., Xia, S., Horwitz, S. B., Mallen-St, J.,
Guerriero, J. L., Bar-Sagi, D., Veith, J. M., Pera, P., and Bernacki,
R. J. (2008) Design, synthesis, and biological evaluation of new-
generation taxoids. J. Med. Chem. 51, 3203–3221.
(38) Pires, M. M., and Chmielewski, J. (2008) Fluorescence
imaging of cellular glutathione using a latent rhodamine. Org.
Lett. 10, 837–840.
(39) Adamczyk, M., Grote, J., and Moore, J. A. (1999) Chemoen-
zymic synthesis of 3′-O-(carboxyalkyl)fluorescein labels. Bio-
conjugate Chem. 10, 544–547.
(24) Ojima, I. (2004) Use of fluorine in the medicinal chemistry
and chemical biology of bioactive compoundssa case study
on fluorinated taxane anticancer agents. ChemBioChem 5, 628–
635.
(25) Zheng, Z.-B., Zhu, G., Tak, H., Joseph, E., Eiseman, J. L.,
and Creighton, D. J. (2005) N-(2-Hydroxypropyl)methacrylamide
copolymers of a glutathione (GSH)-activated glyoxalase I
inhibitor and DNA alkylating agent: synthesis, reaction kinetics
with GSH, and in vitro antitumor activities. Bioconjugate Chem.
16, 598–607.
(26) Kosower, N. S., and Kosower, E. M. (1978) The glutathione
status of cells. Int. ReV. Cytol. 54, 109–160.
(27) Meister, A. (1983) Metabolism and transport of glutathione
and other γ-glutamyl compounds, In Functions of Glutathione:
Biochemical, Physiological, Toxicological, and Clinical Aspects
(Larsson, A., Ed.), pp 1-22, Raven Press, New York.
(40) Liu, F., Zha, H.-Y., and Yao, Z.-J. (2003) Synthesis of a new
conformation-constrained L-Tyrosine analogue as a potential
scaffold for SH2 domain ligands. J. Org. Chem. 68, 6679–6684.
(41) Mukherjee, S., Ghosh, R. N., and Masfield, F. R. (1997)
Endocytosis. Physiol. ReV. 77, 759–803.
(42) Silverstein, S. C., Steinman, R. M., and Cohn, Z. A. (1977)
Annu. ReV. Biochem. 46, 669–722.
(43) Schmid, S. L., and Carter, L. L. (1990) ATP is required for
receptor-mediated endocytosis in intact cells. J. Cell Biol. 111,
2307–2318.
(44) Hong, R., Han, G., Fernandez, J. M., Kim, B., Forbes, N. S.,
and Rotello, V. M. (2006) Glutathione-mediated delivery and
release using monolayer protected nanoparticle carriers. J. Am.
Chem. Soc. 128, 1078–1079.
BC9005656